FY2025 Earnings Forecast for ELAN Issued By Leerink Partnrs

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Leerink Partnrs boosted their FY2025 earnings per share estimates for Elanco Animal Health in a research report issued on Thursday, July 17th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings per share of $0.85 for the year, up from their prior estimate of $0.84. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health's Q4 2025 earnings at $0.15 EPS and FY2026 earnings at $0.95 EPS.

Other equities analysts have also issued reports about the company. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective on the stock in a research report on Thursday. Stifel Nicolaus increased their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Finally, Wall Street Zen upgraded Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of "Moderate Buy" and an average target price of $16.00.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN traded down $0.18 during mid-day trading on Friday, hitting $14.78. The company had a trading volume of 3,045,323 shares, compared to its average volume of 5,032,333. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $15.78. The stock's 50-day moving average price is $13.82 and its 200-day moving average price is $11.79. The company has a current ratio of 2.71, a quick ratio of 1.46 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $7.34 billion, a price-to-earnings ratio of 19.97, a P/E/G ratio of 2.92 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.31 by $0.06. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The company's revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.34 earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC increased its holdings in shares of Elanco Animal Health by 1,153.6% in the 4th quarter. FMR LLC now owns 40,232,327 shares of the company's stock worth $487,213,000 after purchasing an additional 37,022,891 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after purchasing an additional 2,563,740 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Elanco Animal Health by 1.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company's stock worth $167,826,000 after purchasing an additional 292,655 shares in the last quarter. Shapiro Capital Management LLC increased its holdings in shares of Elanco Animal Health by 7.5% in the 4th quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company's stock worth $149,640,000 after purchasing an additional 862,900 shares in the last quarter. Finally, Magnetar Financial LLC increased its holdings in shares of Elanco Animal Health by 13.7% in the 4th quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock worth $145,711,000 after purchasing an additional 1,454,082 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.